市场调查报告书
商品编码
1380431
全球微电子医疗植入物市场2023-2030Global Microelectronic Medical Implants Market 2023-2030 |
全球微电子医疗植入物市场预计在预测期内(2023-2030年)CAGR为11.1%。该市场的成长归因于全球神经系统疾病盛行率的增加。结果表明,一个主要因素是神经系统疾病发病率的上升。除了上述疾病的负担之外,对神经刺激器等有效治疗的需求也在增加。根据美国国立卫生研究院的数据,到 2023 年 5 月,神经系统疾病非常普遍,导致全球 900 万人死亡,占伤残调整生命年的 42.2%。伤残调整生命年的五种最常见的神经原因是中风(42.2%)、头痛(偏头痛,16.3%)、失智症(10.4%)、脑膜炎(7.9%)和癫痫(4.9%)。此外,遗传性神经代谢疾病包括 1,400 多种不同的遗传疾病,新生儿的发生率为 800 分之一到 2,500 分之一。
全球微电子医疗植入物市场按产品和技术进行细分。根据产品,市场细分为心律调节器和除颤器、神经刺激器、植入式药物输送装置、脊椎融合刺激器、人工耳蜗等。此外,根据技术,市场细分为射频、感测器等。心律调节器和除颤器子类别预计将占据吸收器产品的很大一部分市场份额。这是由于老年人口的增加和心臟病发病率的上升。心臟阻塞和心搏过缓是涉及患者可以使用心律调节器的常见疾病。
其中,人工耳蜗子细分市场预计将在全球微电子医疗植入物市场中占据相当大的份额。细分市场的成长归因于听力损失的盛行率不断上升。资料显示,听力损失在成人和儿童中都很常见。由于人工耳蜗等助听器的普及率持续上升,对助听器的需求也不断增加。根据世界卫生组织 (WHO) 的数据,2023 年 2 月,全球约 5% 的人口(4.3 亿人)患有残疾性听力损失,其中 4.32 亿成年人,其中 3,400 万名儿童。到 2050 年,估计残疾性听力损失的人数将增加到 7 亿(每 10 人就有 1 人)。大多数受致残性听力损失影响的人生活在低收入和中等收入国家。听力损失的盛行率随着年龄的增长而增加; 60 岁以上的人中有 25% 患有残疾性听力损失。
全球微电子医疗植入物市场根据地理位置进一步细分,包括北美(美国和加拿大)、欧洲(英国、义大利、西班牙、德国、法国和欧洲其他地区)、亚太地区(印度、中国、日本、韩国和亚洲其他地区)以及世界其他地区(中东和非洲以及拉丁美洲)。其中,由于医疗保健成本不断增长、人口老化和慢性病发病率高,预计亚太地区将在全球市场中占据显着份额。根据 MDPI 预测,到 2021 年 12 月,预计到 2050 年,全球约有 21 亿人年龄在 60 岁及以上。人口成长需要增加公共医疗保健服务,因为老年人更有可能患有慢性病。超过三分之二的死亡是由慢性疾病造成的,其中 30% 是由心血管疾病造成的。目前,有超过 1.8 亿人患有糖尿病,估计到 2030 年这一数字可能达到 3.6 亿。
在所有地区中,北美地区预计在预测期内将以相当大的CAGR成长。区域成长归因于该地区对技术进步的需求不断增长。随着微电子和感测器技术的进步,植入式感测器变得更小、更精确、更节能,从而提高了它们在一系列医疗应用中的可行性。据美国国立卫生研究院 (gov.) 称,2023 年 9 月,植入式感测器在医疗保健领域具有一系列潜在应用,有望彻底改变医疗保健 5.0。新的医疗保健时代将聚焦于智慧疾病控制和检测、虚拟护理、智慧健康管理、智慧监测和决策。植入式感测器将实现高精度的连续生理监测,从而促进人工智慧和物联网与医疗设备和治疗的整合。此外,近年来,与感测器相关的出版物、公司和临床试验不断增加,并有许多综述论文。植入式感测器市场价值几乎是穿戴式感测器市场价值3.2768亿美元的15倍。可穿戴感测器市场预计将快速成长。
服务于微电子医疗植入物市场的主要公司包括: Boston Scientific Corp.、Cochlear Ltd.、Crunchbase、Envoy Medical Corp.、LivaNova PLC 等。市场参与者透过各种策略(包括併购、合作、合作、融资和新产品发布),为市场成长做出了巨大贡献,以保持市场竞争力。例如,2022年11月,Alleima收购了Endosmart,除了手术器械外,它还提供肾结石取出篮和圈套器、乳癌肿瘤标记等产品。
Title: Global Microelectronic Medical Implants Market Size, Share & Trends Analysis Report by Product (Pacemakers & Defibrillators, Neurostimulators, Implantable Drug Delivery Devices, Spinal Fusion Stimulators, Cochlear Implants, and Others), and by Technology (Radiofrequency, Sensors, and Others),Forecast Period (2023-2030).
The global microelectronic medical implants market is anticipated to grow at a CAGR of 11.1% during the Forecast Period (2023-2030). The market's growth is attributed to increasing prevalence of neurological disorders across the globe. The results show that one major factor is the rising incidence of neurological disorders. The need for efficient treatments such as neurostimulators rises in addition to the burden of the aforementioned diseases. According to the National Institute of Health, in May 2023, neurological disorders are highly prevalent, accounting for 9 million deaths and 42.2% of disability-adjusted life years worldwide. The five most common neurological causes of disability-adjusted life years were stroke (42.2%), headaches (migraine, 16.3%), dementias (10.4%), meningitis (7.9%) and epilepsy (4.9%). In addition, inherited neurometabolic diseases, which comprise more than 1,400 different genetic diseases, have an incidence of between 1 in 800 to 1 in 2,500 newborns.
The global microelectronic medical implants market is segmented on the product, and technology. Based on the product, the market is sub-segmented into pacemakers & defibrillators, neurostimulators, implantable drug delivery devices, spinal fusion stimulators, cochlear implants, and others. Furthermore, based on the technology, the market is sub-segmented into radiofrequency, sensors, and others. The pacemakers & defibrillators subcategory is expected to capture a significant portion of the market share within the absorber product. This is attributed to the increasing elderly population and rising incidence of heart diseases. Heart obstruction and bradycardia are frequent ailments involving a patient can utilize a pacemaker.
Among the product, the cochlear implants sub-segment is expected to hold a considerable share of the global microelectronic medical implants market. The segmental growth is attributed to the growing prevalence of hearing loss. The data show that hearing loss is prevalent in both adults and children. The need for hearing aids such as cochlear implants is growing since its prevalence retains rising. According to the World Health Organization (WHO), in February 2023, around 5% of the global population (430 million people) has disabling hearing loss, with adults making up 432 million of those people and 34 million of them being children. By 2050, it is estimated that the number of individuals with disabling hearing loss will have risen to 700 million (1 in every 10 people). The majority of those affected by disabling hearing loss live in low- and middle-income countries. The prevalence of hearing loss increases with age; 25% of those over 60 years old have disabling hearing loss.
The global microelectronic medical implants market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the growing healthcare costs, an aging population, and the incidence of chronic diseases. According to MDPI, in December 2021, by 2050, it is estimated that approximately 2.1 billion individuals globally will be aged 60 and over. This population growth has created a need for increased public healthcare services, as elderly individuals are more likely to suffer from chronic diseases. Chronic illnesses are responsible for more than two-thirds of all deaths and cardiovascular diseases account for 30 percent of those deaths. Currently, over 180 million individuals have diabetes, with estimates suggesting that number could reach 360 million by 2030.
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising demand for technological advancements across the region. As microelectronics and sensor technology progress, implantable sensors grow smaller, more precise, more energy-efficient, improving their viability for a range of medical applications. According to the National Institute of Health (gov.), in September 2023, implantable sensors have a range of potential applications in healthcare, with the promise of revolutionizing Healthcare 5.0. This new era of healthcare will focus on smart disease control and detection, virtual care, intelligent health management, smart monitoring, and decision-making. Implantable sensors will enable continuous physiological monitoring with a high level of accuracy, which could facilitate the integration of artificial intelligence and the Internet of Things with medical devices and treatment. Furthermore, recent years, there has been a rise in publications, companies, and clinical trials related to sensors, with many review papers available. The market for implantable sensors is valued at almost 15 times that of the wearable sensor market, which was valued at USD 327.68 million. The market for wearable sensors is expected to increase rapidly.
The major companies serving the microelectronic medical implants market include: Boston Scientific Corp., Cochlear Ltd., Crunchbase, Envoy Medical Corp., LivaNova PLC and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2022, Alleima acquired Endosmart, It offers a product includes kidney stone retrieval baskets and snares, and breast cancer tumor markers, in addition to surgical instruments.